Gut bacteria capsule could slow fatty liver disease
Disease control
Recruiting now
This early-stage study tests a pasteurized probiotic (pAKK_LWHK0003) in 40 adults with metabolic fatty liver disease (MASLD). The goal is to see if the capsule safely reduces liver fat and scarring over 12 to 16 weeks. Participants take different doses or a placebo. The approach …
Phase: PHASE1 • Sponsor: Leeuwenhoek Laboratories Co. Ltd. • Aim: Disease control
Last updated May 10, 2026 17:55 UTC